GlassScriptPhysician profile
Tram Vo
NPI 1073214672
$3,064.62
in general payments reported to CMS, 2019-2025
20 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $238 · 2024: $1,548 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $695.69 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $522.11 | 2024-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $376.47 | 2023-2025 | |
| Amgen INC. | $280.05 | 2023-2025 | Repatha, Otezla, Evenity |
| Radius Health, INC. | $151.15 | 2024-2025 | Tymlos |
| Idorsia Pharmaceuticals US INC | $136.15 | 2023-2024 | Quviviq |
| Heartflow, INC. | $129.38 | 2025 | |
| Paratek Pharmaceuticals, INC. | $122.32 | 2024-2025 | Nuzyra, Xhance |
| Glaxosmithkline, LLC. | $114.11 | 2024-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $95.03 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.15 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $76.69 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $76.04 | 2024-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $54.33 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.63 | 2024-2025 | Xifaxan |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24.94 | 2023 | |
| Alexion Pharmaceuticals, INC. | $23.91 | 2024 | Ultomiris |
| Corcept Therapeutics | $22.72 | 2024 | Korlym |
| Dexcom, INC. | $20.62 | 2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $18.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tram Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.